RELAPSED CANCER

This study tests whether teclistamab, a drug for relapsed/refractory multiple myeloma, can be given safely in an outpatient setting instead of requiring a hospital stay. It involves 15 patients who have already tried at least three other treatments. The goal is to reduce hospital…

This study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. About 64 adults who have already tri…

This study tests a combination of two drugs, zanubrutinib and pemetrexed, in people whose central nervous system lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and control the disease. About 15 participants will re…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults whose multiple myeloma has returned or stopped responding to treatment. The main goal is to see how many patients respond to this drug cocktail. This is n…

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…

This study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The goal is to find safe doses …

This study tests a new drug, epcoritamab, combined with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if this combination can shrink or eliminate the cancer. After three cycles, patients may pro…